ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Implications of Stemness Features in 1059 Hepatocellular Carcinoma Patients from Five Cohorts: Prognosis, Treatment Response, and Identification of Potential Compounds

Mai, Haoming; Xie, Haisheng; Luo, Mengqi; Hou, Jia; Chen, Jiaxuan; Hou, Jinlin*; Jiang, De-ke*南方医科大学
Cancers2022-2DOI: 10.3390/cancers14030563
8被引6阅读
引用收藏
分享

摘要

Simple Summary Cancer stemness has been reported to drive hepatocellular carcinoma (HCC) tumorigenesis and treatment resistance. However, comprehensive interpretations of transcriptomic stemness features in HCC patients have not been conducted in multiple cohorts. Our aim was to interpret clinical and therapeutic implications of transcriptional stemness features and explore potential compounds for HCC treatment. We found that transcriptional stemness indexes (mRNAsi) were independently associated with worse HCC prognosis. The HCC stemness risk model (HSRM) developed in this study significantly predicted prognosis and treatment response in various HCC cohorts. Analysis of two stemness subtypes suggested several liver-specific metabolic pathways, and mutations of TP53 and RB1 were associated with HCC transcriptional stemness. Moreover, we also identified potential compounds that target HCC transcriptional stemness. Our findings comprehensively characterized transcriptional stemness as a risk factor in HCC progression and treatment. Cancer stemness has been reported to drive hepatocellular carcinoma (HCC) tumorigenesis and treatment resistance. In this study, five HCC cohorts with 1059 patients were collected to calculate transcriptional stemness indexes (mRNAsi) by the one-class logistic regression machine learning algorithm. In the TCGA-LIHC cohort, we found mRNAsi was an independent prognostic factor, and 626 mRNAsi-related genes were identified by Spearman correlation analysis. The HCC stemness risk model (HSRM) was trained in the TCGA-LIHC cohort and significantly discriminated overall survival in four independent cohorts. HSRM was also significantly associated with transarterial chemoembolization treatment response and rapid tumor growth in HCC patients. Consensus clustering was conducted based on mRNAsi-related genes to divide 1059 patients into two stemness subtypes. On gene set variation analysis, samples of subtype I were found enriched with pathways such as DNA replication and cell cycle, while several liver-specific metabolic pathways were inhibited in these samples. Somatic mutation analysis revealed more frequent mutations of TP53 and RB1 in the subtype I samples. In silico analysis suggested topoisomerase, cyclin-dependent kinase, and histone deacetylase as potential targets to inhibit HCC stemness. In vitro assay showed two predicted compounds, Aminopurvalanol-a and NCH-51, effectively suppressed oncosphere formation and impaired viability of HCC cell lines, which may shed new light on HCC treatment.

学科与关键词

关键词
stemnesshepatocellular carcinomamRNAsiprognosistreatment responseOCLR
相关
加载中…
  • mRNAsi-related genes can effectively distinguish hepatocellular carcinoma into new molecular subtypes
    Wang, Canbiao; Qin, Shijie; Pan, Wanwan; Shi, Xuejia; Gao, Hanyu; Jin, Ping*; Xia, Xinyi*; Ma, Fei*Computational and Structural Biotechnology Journal, 2022, 20: 2928-2941.被引 5
  • Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients
    Chen, Dongjie; Liu, Jixing; Zang, Longjun; Xiao, Tijun; Zhang, Xianlin; Li, Zheng; Zhu, Hongwei*; Gao, Wenzhe*; Yu, Xiao*International Journal of Biological Sciences, 2022, 18(1): 360-373.被引 44
  • Stemness Analysis Uncovers That The Peroxisome Proliferator-Activated Receptor Signaling Pathway Can Mediate Fatty Acid Homeostasis In Sorafenib-Resistant Hepatocellular Carcinoma Cells
    Feng, Tingze; Wu, Tianzhi; Zhang, Yanxia; Zhou, Lang; Liu, Shanshan; Li, Lin; Li, Ming; Hu, Erqiang; Wang, Qianwen; Fu, Xiaocong; Zhan, Li; Xie, Zijing; Xie, Wenqin; Huang, Xianying*; Shang, Xuan*; Yu, Guangchuang*Frontiers in Oncology, 2022, 12: 912694.被引 7
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancers
发表日期
2022-02
卷期
第 14 卷, 第 3 期
页码
563
DOI
10.3390/cancers14030563
期刊等级
2区
成果收录
SCIE
资助标注
Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program [2017BT01S131]; National Natural Science Foundation of China [81472618, 81670535, 81802828, 81802833]; Natural Science Foundation of Guangdong Province [2019A1515011423]; National Science and Technology Major Project [2018ZX10301202, 2017ZX10202202]; Key-Area Research and Development Program of Guangdong Province [2019B020227004]; Innovative Research Team Project of Guangxi Province [2017GXNSFGA198002]; Dean Fund of Nanfang Hospital, Southern Medical University [2018Z005]

作者

  • M

    Mai, Haoming (第一作者)

    southern med univ

  • X

    Xie, Haisheng

    southern med univ

查看全部 7 位作者收起作者
  • L

    Luo, Mengqi

    southern med univ

  • H

    Hou, Jia

    southern med univ

  • C

    Chen, Jiaxuan

    southern med univ

  • H

    Hou, Jinlin (通讯)

    southern med univ

  • J

    Jiang, De-ke (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417